Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Sees Significant Decline in Short Interest

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,377,300 shares, a decrease of 7.8% from the December 15th total of 1,494,600 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 13,773.0 days.

Wall Street Analysts Forecast Growth

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research report on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Price Performance

Shares of BIOVF opened at $28.30 on Friday. Swedish Orphan Biovitrum AB has a 1 year low of $22.87 and a 1 year high of $32.25. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49. The stock has a 50 day simple moving average of $28.41 and a two-hundred day simple moving average of $28.41. The firm has a market cap of $10.07 billion, a P/E ratio of 41.62 and a beta of 0.51.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.